Zobrazeno 1 - 10
of 622
pro vyhledávání: '"EGFR-tyrosine kinase inhibitor"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-19 (2024)
Abstract Background There is a growing interest in utilizing a combination of brain radiotherapy (RT) and tyrosine kinase inhibitors (TKIs) for patients diagnosed with brain metastases (BM) in epidermal growth factor receptor (EGFR) mutation-positive
Externí odkaz:
https://doaj.org/article/6bd9a9f167024c33910c7a7c8db4c14b
Autor:
Hiroshi Yoshida, Hiroaki Ozasa, Kentaro Hashimoto, Yusuke Shima, Keiichiro Suminaga, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masahiro Yoshioka, Masashi Kanai, Takehito Shukuya, Manabu Muto, Toyohiro Hirai
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 14, Iss , Pp 100286- (2024)
Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for
Externí odkaz:
https://doaj.org/article/9c163bc24b6e4a9181dc97cc3c256896
Autor:
Xiaosheng Ding, Weiwei Shi, Bingxuan Han, Hanxiao Chen, Jia Li, Juan An, Lili Zhou, Weiran Xu, Hui Shi, Xixi Zheng, Yichun Hua, Xiaoyan Li
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2934-2940 (2023)
Abstract Background The absence of thyroid transcription factor 1 (TTF‐1) is associated with a lower frequency of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LUAD). The aim of this study was to assess the impact of TTF
Externí odkaz:
https://doaj.org/article/7b3421b022c743a0b916d79b59f98a63
Autor:
Sho Mitsuya, MD, Masahiro Arai, MD, Kiyoe Kanaoka, MD, Tomoya Funamoto, MD, Hiroyuki Tsuji, MD, Kenjiro Tsuruoka, MD, PhD, Ninso Matsunaga, MD, Takahiko Nakamura, MD, Yosuke Tamura, MD, PhD, Masafumi Imanishi, MD, PhD, Soichiro Ikeda, MD, PhD, Akihisa Imagawa, MD, PhD, Yasuhito Fujisaka, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100631- (2024)
Osimertinib administration has been approved as an adjuvant treatment after complete surgical resection in patients with EGFR-mutated NSCLC. This article presents the first report of life-threatening postoperative osimertinib-induced interstitial lun
Externí odkaz:
https://doaj.org/article/26d3d531b4c84fe79dd21d8013090533
Autor:
Chen Shi, Cong Zhang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Wang, Shijun Li, Yu Zhang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 6, Pp 2613-2627 (2023)
Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%–20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfact
Externí odkaz:
https://doaj.org/article/042083c0f0b24c0e8de95297a5585825
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The treatment paradigm for advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anti-programmed death-1 (PD-1) antibodies have increasingly been incor
Externí odkaz:
https://doaj.org/article/8e42f254810240bfb35f1bb992b16004
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100525- (2023)
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treat
Externí odkaz:
https://doaj.org/article/27b3e58854a34814b01a239b63d7e6ea
Autor:
Hainan Yang, Lei Wen, Yingying Pan, Changguo Shan, Weiping Hong, Hui Wang, Cheng Zhou, Linbo Cai, Caicun Zhou
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide a better prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). Nevertheless, the outcome of leptomeningeal metastasis (LM) remains poor. In add
Externí odkaz:
https://doaj.org/article/7931c9e1e3c640b69c9ccd3c0e19b3cc
Autor:
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 386-393 (2022)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed f
Externí odkaz:
https://doaj.org/article/4ed061c67bdb4b24926d74df2d3d685d